首页 > 最新文献

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova最新文献

英文 中文
[Tardive dyskinesia]. [迟发性运动障碍]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307125
Z A Zalyalova
Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non-psychiatric prescriptions. Replacement of antipsychotics with lower affinity for D2 receptors drugs, addition of VMAT2 (tetrabenazine), botulinum therapy, amantadine may be effective. In detection and incurable cases, the possibility of neuromodulation of brain structures should be considered. Most methods for testing TD currently have an insufficient level of evidence, although they include recommendations from professional communities. There is a great need for new clinical trials.
迟发性运动障碍(TD)是一种迟发性,通常是不可逆的医源性运动障碍,由长期使用多巴胺受体阻断药物引起。预防TD是最重要的,临床医生应该遵循处方抗精神病药物的最佳实践建议,并减少在非精神科处方中使用多巴胺受体阻断药物。替代对D2受体亲和力较低的抗精神病药物,加入VMAT2 (tetrabenazine),肉毒杆菌治疗,金刚烷胺可能有效。在发现和无法治愈的病例中,应考虑大脑结构神经调节的可能性。大多数检测TD的方法目前证据不足,尽管它们包括专业团体的建议。迫切需要新的临床试验。
{"title":"[Tardive dyskinesia].","authors":"Z A Zalyalova","doi":"10.17116/jnevro202312307125","DOIUrl":"https://doi.org/10.17116/jnevro202312307125","url":null,"abstract":"Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non-psychiatric prescriptions. Replacement of antipsychotics with lower affinity for D2 receptors drugs, addition of VMAT2 (tetrabenazine), botulinum therapy, amantadine may be effective. In detection and incurable cases, the possibility of neuromodulation of brain structures should be considered. Most methods for testing TD currently have an insufficient level of evidence, although they include recommendations from professional communities. There is a great need for new clinical trials.","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prevalence and risk factors of delirium in COVID-19]. [COVID-19患者谵妄的患病率及危险因素]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307186
Yu G Tikhonova, M A Kinkulkina, A V Volkov, V A Sedelkova, T I Avdeeva, T A Izyumina, M A Makarova, T N Maximova, M Yu Brovko, S V Moiseev, N N Ivanets

Objective: To assess the frequency and risk factors of delirium in patients hospitalized with COVID-19.

Material and methods: Four hundred and forty patients admitted to the Infectious Diseases Hospital of the University Clinical Hospital No.3 of Sechenov University were included in the study. The Patient Health Questionnaire (PHQ-9), the Generalized Anxiety Disorder Screening Questionnaire-7 (GAD-7), the Insomnia Severity Index (ISI), the Delirium severity rating scale (DRS-R-98) were administered.

Results: Delirium was detected in 27.8% of patients. Significant risk factors were age (p=0.002), severity of respiratory failure (p=0.005), concomitant somatic disease (p=0.003), and respiratory therapy (p<0.001). There was an association between severe anxiety (p<0.001) and insomnia (p=0.07) observed at admission with the risk of developing delirium during the hospital stay.

Conclusion: The study reveals a high prevalence of delirium in patients with COVID-19. In order to prevent delirium and/or reduce the risk, early diagnosis and identification of preclinical forms are of particular importance.

目的:了解新型冠状病毒肺炎住院患者谵妄发生频率及危险因素。材料与方法:选取谢切诺夫大学第三大学临床医院感染性医院住院的440例患者为研究对象。采用患者健康问卷(PHQ-9)、广泛性焦虑障碍筛查问卷-7 (GAD-7)、失眠严重程度指数(ISI)、谵妄严重程度评定量表(DRS-R-98)。结果:谵妄发生率为27.8%。入院时观察到年龄(p=0.002)、呼吸衰竭严重程度(p=0.005)、伴发躯体疾病(p=0.003)和呼吸治疗(ppp=0.07)为住院期间发生谵妄的危险因素。结论:新冠肺炎患者谵妄发生率高。为了预防谵妄和/或降低风险,早期诊断和临床前形式的识别是特别重要的。
{"title":"[Prevalence and risk factors of delirium in COVID-19].","authors":"Yu G Tikhonova,&nbsp;M A Kinkulkina,&nbsp;A V Volkov,&nbsp;V A Sedelkova,&nbsp;T I Avdeeva,&nbsp;T A Izyumina,&nbsp;M A Makarova,&nbsp;T N Maximova,&nbsp;M Yu Brovko,&nbsp;S V Moiseev,&nbsp;N N Ivanets","doi":"10.17116/jnevro202312307186","DOIUrl":"https://doi.org/10.17116/jnevro202312307186","url":null,"abstract":"<p><strong>Objective: </strong>To assess the frequency and risk factors of delirium in patients hospitalized with COVID-19.</p><p><strong>Material and methods: </strong>Four hundred and forty patients admitted to the Infectious Diseases Hospital of the University Clinical Hospital No.3 of Sechenov University were included in the study. The Patient Health Questionnaire (PHQ-9), the Generalized Anxiety Disorder Screening Questionnaire-7 (GAD-7), the Insomnia Severity Index (ISI), the Delirium severity rating scale (DRS-R-98) were administered.</p><p><strong>Results: </strong>Delirium was detected in 27.8% of patients. Significant risk factors were age (<i>p</i>=0.002), severity of respiratory failure (<i>p</i>=0.005), concomitant somatic disease (<i>p</i>=0.003), and respiratory therapy (<i>p</i><0.001). There was an association between severe anxiety (<i>p</i><0.001) and insomnia (<i>p</i>=0.07) observed at admission with the risk of developing delirium during the hospital stay.</p><p><strong>Conclusion: </strong>The study reveals a high prevalence of delirium in patients with COVID-19. In order to prevent delirium and/or reduce the risk, early diagnosis and identification of preclinical forms are of particular importance.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Knee range of motion as a marker of the effectiveness of medical intervention in multiple sclerosis]. [膝关节活动度作为多发性硬化症医学干预有效性的标志]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307284
S A Ryabov, A N Boyko

Objective: To measure the knee range of motion (ROM) in the sagittal plane by video analysis in patients with multiple sclerosis (MS) after a course of medical rehabilitation and determine the minimal clinically important differences (MCID).

Material and methods: We examined 45 patients (37 women, 8 men) with relapsing-remitting (n=38) and secondary-progressive MS before and after a course of medical rehabilitation. Gait parameters were recorded on video analysis system Physiomed Smart («Physiomed», Germany, the Davis protocol).

Results: The course of complex medical rehabilitation contributes to an increase knee ROM in MS patients in a wide range of disability (EDSS <6.5 points). MCID is estimated as 7.14° in mild (EDSS ≤4.0) and as 7.67° in moderate (EDSS=4.5-5.5) gait impairment.

Conclusion: The results will assist clinicians and researchers in interpreting the significance of observed kinematic changes in the knee joint in MS patients after medical intervention.

目的:通过视频分析测量多发性硬化症(MS)患者经过一个医学康复疗程后的膝关节矢状面活动度(ROM),确定最小临床重要差异(MCID)。材料和方法:我们检查了45例复发缓解型(n=38)和继发性进展性MS患者(37名女性,8名男性)在一个医学康复疗程前后。步态参数记录在视频分析系统Physiomed Smart(«Physiomed»,德国,戴维斯协议)上。结论:本研究结果将有助于临床医生和研究人员解释医学干预后MS患者膝关节运动变化的意义。
{"title":"[Knee range of motion as a marker of the effectiveness of medical intervention in multiple sclerosis].","authors":"S A Ryabov,&nbsp;A N Boyko","doi":"10.17116/jnevro202312307284","DOIUrl":"https://doi.org/10.17116/jnevro202312307284","url":null,"abstract":"<p><strong>Objective: </strong>To measure the knee range of motion (ROM) in the sagittal plane by video analysis in patients with multiple sclerosis (MS) after a course of medical rehabilitation and determine the minimal clinically important differences (MCID).</p><p><strong>Material and methods: </strong>We examined 45 patients (37 women, 8 men) with relapsing-remitting (<i>n=</i>38) and secondary-progressive MS before and after a course of medical rehabilitation. Gait parameters were recorded on video analysis system Physiomed Smart («Physiomed», Germany, the Davis protocol).</p><p><strong>Results: </strong>The course of complex medical rehabilitation contributes to an increase knee ROM in MS patients in a wide range of disability (EDSS <6.5 points). MCID is estimated as 7.14° in mild (EDSS ≤4.0) and as 7.67° in moderate (EDSS=4.5-5.5) gait impairment.</p><p><strong>Conclusion: </strong>The results will assist clinicians and researchers in interpreting the significance of observed kinematic changes in the knee joint in MS patients after medical intervention.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10027486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The influence of fluoxetine on neuroimmune interaction in multiple sclerosis]. [氟西汀对多发性硬化患者神经免疫相互作用的影响]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307265
M V Melnikov, A V Lopatina, A A Sviridova, M V Pashenkov, A N Boyko

Objective: To study the effect of fluoxetine on Th17- and Th1-immune response, which plays an important role in the pathogenesis of multiple sclerosis (MS).

Material and methods: Ten patients with relapsing-remitting MS and ten healthy subjects were examined. The functions of Th17- and Th1-immune responses were assessed by the production of cytokines interleukin-17 (IL-17) and interferon-gamma (IFN-γ) by CD4+ T cells stimulated with macrophages or microbeads coated with anti-CD3 and anti-CD28-antibodies. To assess the effect of fluoxetine on the macrophages-induced Th17- and Th1-immune response, macrophages were pre-incubated in the presence of fluoxetine and co-cultured with autologous CD4+ T-cells. In the case of stimulation of CD4+ T-cells with anti-CD3/CD28-microbeads, fluoxetine was added directly to the T-helper cells before adding of microbeads. In addition, we evaluated the effect of fluoxetine on the production of the factors of differentiation of Th17-cells cytokines IL-6 and IL-1β by macrophages. The levels of cytokines in the cell culture supernatants were measured by ELISA.

Results: The production of IL-17 and IFN-γ by CD4+ T-cells stimulated with macrophages or anti-CD3/CD28-microbeads was comparable between the groups. Fluoxetine suppressed the production of IL-17 and IFN-γ by anti-CD/CD28-stimulated CD4+ T-cells in both groups. Fluoxetine also suppressed the production of IL-6 and IL-1β by macrophages as well as their ability to induce IL-17 and IFN-γ production by CD4+ T-cells in both groups.

Conclusions: Fluoxetine may have an anti-inflammatory effect in MS that could be mediated by suppression of Th17- and Th1-cells or macrophage-induced Th17- and Th1-immune response.

目的:研究氟西汀对Th17-和th1免疫反应的影响,Th17-和th1免疫反应在多发性硬化症(MS)发病中起重要作用。材料和方法:对10例复发-缓解型多发性硬化症患者和10例健康人进行检查。通过巨噬细胞或包被抗cd3和抗cd28抗体的微珠刺激CD4+ T细胞产生细胞因子白介素-17 (IL-17)和干扰素-γ (IFN-γ)来评估Th17-和th1免疫应答的功能。为了评估氟西汀对巨噬细胞诱导的Th17-和th1免疫反应的影响,将巨噬细胞在氟西汀的存在下预孵育,并与自体CD4+ t细胞共培养。在用抗cd3 / cd28微珠刺激CD4+ t细胞的情况下,在添加微珠之前,将氟西汀直接加入t辅助细胞。此外,我们还评估了氟西汀对巨噬细胞产生th17细胞分化因子IL-6和IL-1β的影响。ELISA法检测细胞培养上清液中细胞因子水平。结果:巨噬细胞或抗cd3 / cd28微珠刺激CD4+ t细胞产生的IL-17和IFN-γ在两组之间具有可比性。氟西汀抑制两组抗cd / cd28刺激的CD4+ t细胞产生IL-17和IFN-γ。氟西汀还抑制了两组巨噬细胞产生IL-6和IL-1β,以及它们诱导CD4+ t细胞产生IL-17和IFN-γ的能力。结论:氟西汀可能通过抑制Th17-和th1细胞或巨噬细胞诱导的Th17-和th1免疫反应而对MS具有抗炎作用。
{"title":"[The influence of fluoxetine on neuroimmune interaction in multiple sclerosis].","authors":"M V Melnikov,&nbsp;A V Lopatina,&nbsp;A A Sviridova,&nbsp;M V Pashenkov,&nbsp;A N Boyko","doi":"10.17116/jnevro202312307265","DOIUrl":"https://doi.org/10.17116/jnevro202312307265","url":null,"abstract":"<p><strong>Objective: </strong>To study the effect of fluoxetine on Th17- and Th1-immune response, which plays an important role in the pathogenesis of multiple sclerosis (MS).</p><p><strong>Material and methods: </strong>Ten patients with relapsing-remitting MS and ten healthy subjects were examined. The functions of Th17- and Th1-immune responses were assessed by the production of cytokines interleukin-17 (IL-17) and interferon-gamma (IFN-γ) by CD4<sup>+</sup> T cells stimulated with macrophages or microbeads coated with anti-CD3 and anti-CD28-antibodies. To assess the effect of fluoxetine on the macrophages-induced Th17- and Th1-immune response, macrophages were pre-incubated in the presence of fluoxetine and co-cultured with autologous CD4<sup>+</sup> T-cells. In the case of stimulation of CD4<sup>+</sup> T-cells with anti-CD3/CD28-microbeads, fluoxetine was added directly to the T-helper cells before adding of microbeads. In addition, we evaluated the effect of fluoxetine on the production of the factors of differentiation of Th17-cells cytokines IL-6 and IL-1β by macrophages. The levels of cytokines in the cell culture supernatants were measured by ELISA.</p><p><strong>Results: </strong>The production of IL-17 and IFN-γ by CD4<sup>+</sup> T-cells stimulated with macrophages or anti-CD3/CD28-microbeads was comparable between the groups. Fluoxetine suppressed the production of IL-17 and IFN-γ by anti-CD/CD28-stimulated CD4<sup>+</sup> T-cells in both groups. Fluoxetine also suppressed the production of IL-6 and IL-1β by macrophages as well as their ability to induce IL-17 and IFN-γ production by CD4<sup>+</sup> T-cells in both groups.</p><p><strong>Conclusions: </strong>Fluoxetine may have an anti-inflammatory effect in MS that could be mediated by suppression of Th17- and Th1-cells or macrophage-induced Th17- and Th1-immune response.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[NMDA receptors expression activity in anaplastic astrocytomas]. NMDA受体在间变性星形细胞瘤中的表达活性。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312301197
P V Nikitin, A Y Belyaev, G L Kobyakov, Y V Strunina, S V Shugay, G R Musina, D Y Usachev, P S Timashev

Objective: To study the relationship of NMDA receptors expression activity with proliferative activity and genetic properties of anaplastic astrocytomas, as well as the survival of patients with this disease.

Material and methods: To solve this problem, we compared the expression activity of the least studied NMDA receptors in the context under consideration, detected using immunofluorescent studies and polymerase chain reaction, with the results of histological and molecular studies, the proliferative activity of neoplasms, and the survival of patients.

Results: The expression activity of NMDA receptors is higher in astrocytomas, grade 3, which do not carry mutations in IDH1 and IDH2 genes. In addition, the activity of NMDA receptors expression directly correlates with proliferative activity in the tumors. The activity of NMDA receptor expression has a significant impact on the prognosis of disease-free survival.

Conclusion: We have shown for the first time the significant role of NMDA receptors in the progression of diffuse astrocytomas, which can become the basis for creating new therapeutic and diagnostic tools.

目的:研究NMDA受体表达活性与间变性星形细胞瘤的增殖活性、遗传特性及患者生存率的关系。材料和方法:为了解决这一问题,我们将考虑的情况下研究最少的NMDA受体的表达活性,通过免疫荧光研究和聚合酶链反应检测,与组织学和分子研究结果,肿瘤的增殖活性和患者的生存进行了比较。结果:NMDA受体在3级星形细胞瘤中表达活性较高,不携带IDH1和IDH2基因突变。此外,NMDA受体的表达活性与肿瘤的增殖活性直接相关。NMDA受体的表达活性对无病生存的预后有重要影响。结论:我们首次揭示了NMDA受体在弥漫性星形细胞瘤进展中的重要作用,为开发新的治疗和诊断工具奠定了基础。
{"title":"[NMDA receptors expression activity in anaplastic astrocytomas].","authors":"P V Nikitin,&nbsp;A Y Belyaev,&nbsp;G L Kobyakov,&nbsp;Y V Strunina,&nbsp;S V Shugay,&nbsp;G R Musina,&nbsp;D Y Usachev,&nbsp;P S Timashev","doi":"10.17116/jnevro202312301197","DOIUrl":"https://doi.org/10.17116/jnevro202312301197","url":null,"abstract":"<p><strong>Objective: </strong>To study the relationship of NMDA receptors expression activity with proliferative activity and genetic properties of anaplastic astrocytomas, as well as the survival of patients with this disease.</p><p><strong>Material and methods: </strong>To solve this problem, we compared the expression activity of the least studied NMDA receptors in the context under consideration, detected using immunofluorescent studies and polymerase chain reaction, with the results of histological and molecular studies, the proliferative activity of neoplasms, and the survival of patients.</p><p><strong>Results: </strong>The expression activity of NMDA receptors is higher in astrocytomas, grade 3, which do not carry mutations in <i>IDH1</i> and <i>IDH2</i> genes. In addition, the activity of NMDA receptors expression directly correlates with proliferative activity in the tumors. The activity of NMDA receptor expression has a significant impact on the prognosis of disease-free survival.</p><p><strong>Conclusion: </strong>We have shown for the first time the significant role of NMDA receptors in the progression of diffuse astrocytomas, which can become the basis for creating new therapeutic and diagnostic tools.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10583683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical features of asthenic disorders in chronic heart failure]. 慢性心力衰竭衰弱性疾病的临床特点
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123021104
A V Fomicheva, B A Volel, D V Troshina, D A Andreev, A N Simonov, S A Zozulya, T P Klyushnik

Objective: The aim of the study is to study the clinical features of asthenic disorders in chronic heart failure (CHF) considering the reaction to the disease.

Material and methods: 62 inpatients with CHF II-IV functional class (FC) according to NYHA were examined. Research methods included somatic, psychopathological and pathopsychological examination using psychometric scales.

Results: According to a pathopsychological study using the Multidimensional Fatigue Inventory (MFI-20), asthenic disorders were discovered in all examined patients, realized mainly by «general fatigue» (75.8%) and «physical fatigue» (72.6%), more rarely «mental fatigue» was observed (32.2%). Correlations of «general fatigue» with the age of patients were revealed (p=0.018). There was a relationship between the severity of asthenic disorders and the severity of CHF, as evidenced by the correlation between «general fatigue» and reduced ejection fraction (EF) of the left ventricle (p=0.005), as well as «physical fatigue» and FC according to NYHA (p=0.022). The negative impact of all components of the dimensions of asthenic disorders on the quality of life was determined (p<0.05). According to the concept of the formation of different perceptions of the manifestations of a somatic disease, two types of reactions to asthenic disorders were identified: 1. Dissociative reactions, manifested by a discrepancy between the severity of CHF and a subjective assessment of the condition with an underestimation of the asthenic symptoms denial of its influence on the usual lifestyle and associated with an unfavorable course of CHF and 2. Adaptive reactions, realized by a harmonious perception of asthenia, awareness of the need to change lifestyle considering the presence of CHF symptoms.

Conclusion: In accordance with the results, the described clinical features of asthenic disorders allow to distinguish asthenia in CHF and other pathology, and the identified types of reactions can contribute to the timely verification of asthenia, prevention of further progression of CHF, and the development of appropriate treatment approaches.

目的:探讨慢性心力衰竭(CHF)患者衰弱性疾病的临床特点及对疾病的反应。材料与方法:对62例根据NYHA功能分级(FC)的住院CHF患者进行检查。研究方法包括躯体、精神病理和病理心理检查,采用心理测量量表。结果:根据多维疲劳量表(MFI-20)的病理心理学研究,所有被检查的患者都发现了衰弱障碍,主要表现为“全身疲劳”(75.8%)和“身体疲劳”(72.6%),较少观察到“精神疲劳”(32.2%)。“全身疲劳”与患者年龄相关(p=0.018)。虚弱障碍的严重程度与CHF的严重程度之间存在关系,正如“全身疲劳”与左心室射血分数降低(EF)之间的相关性(p=0.005)以及NYHA中“身体疲劳”与FC之间的相关性(p=0.022)所证明的那样。结论:根据研究结果,所描述的衰弱性疾病的临床特征可以区分CHF中的衰弱和其他病理,识别出的反应类型有助于及时验证虚弱,防止CHF进一步发展,并制定适当的治疗方法。
{"title":"[Clinical features of asthenic disorders in chronic heart failure].","authors":"A V Fomicheva,&nbsp;B A Volel,&nbsp;D V Troshina,&nbsp;D A Andreev,&nbsp;A N Simonov,&nbsp;S A Zozulya,&nbsp;T P Klyushnik","doi":"10.17116/jnevro2023123021104","DOIUrl":"https://doi.org/10.17116/jnevro2023123021104","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study is to study the clinical features of asthenic disorders in chronic heart failure (CHF) considering the reaction to the disease.</p><p><strong>Material and methods: </strong>62 inpatients with CHF II-IV functional class (FC) according to NYHA were examined. Research methods included somatic, psychopathological and pathopsychological examination using psychometric scales.</p><p><strong>Results: </strong>According to a pathopsychological study using the Multidimensional Fatigue Inventory (MFI-20), asthenic disorders were discovered in all examined patients, realized mainly by «general fatigue» (75.8%) and «physical fatigue» (72.6%), more rarely «mental fatigue» was observed (32.2%). Correlations of «general fatigue» with the age of patients were revealed (<i>p</i>=0.018). There was a relationship between the severity of asthenic disorders and the severity of CHF, as evidenced by the correlation between «general fatigue» and reduced ejection fraction (EF) of the left ventricle (<i>p</i>=0.005), as well as «physical fatigue» and FC according to NYHA (<i>p</i>=0.022). The negative impact of all components of the dimensions of asthenic disorders on the quality of life was determined (<i>p</i><0.05). According to the concept of the formation of different perceptions of the manifestations of a somatic disease, two types of reactions to asthenic disorders were identified: 1. Dissociative reactions, manifested by a discrepancy between the severity of CHF and a subjective assessment of the condition with an underestimation of the asthenic symptoms denial of its influence on the usual lifestyle and associated with an unfavorable course of CHF and 2. Adaptive reactions, realized by a harmonious perception of asthenia, awareness of the need to change lifestyle considering the presence of CHF symptoms.</p><p><strong>Conclusion: </strong>In accordance with the results, the described clinical features of asthenic disorders allow to distinguish asthenia in CHF and other pathology, and the identified types of reactions can contribute to the timely verification of asthenia, prevention of further progression of CHF, and the development of appropriate treatment approaches.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Assessment of the safety and clinical efficacy of the Brainmax in therapy of non-demented patients with a mild cognitive impairment]. [评估Brainmax治疗轻度认知障碍非痴呆患者的安全性和临床疗效]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312302183
E V Ekusheva, V B Voitenkov

Objective: The assessment of the clinical efficiency and safety of the drug Brainmax and its influence on the degree of functional recovery in the treatment of patients with non-dementia cognitive disorders with this drug.

Material and methods: An open multicenter randomized study included 60 patients of 18-55 years with light and moderate CI, having complaints of the cognitive spectrum. They used a clinical and neurological study using generally accepted scales and tests (MoCA, MMSE, MFI-20 tests, Schulta, DSST tests and an assessment of the quality of life of SF-36). Patients were randomized in two groups comparable by age and gender. Group 1 was treated with Brainmax per os twice every day for 14 days. After 10-days rest they received same medication for another 14 days. Group 2 was treated with Brainmax per os twice every day for 14 days, without the continuation. The total duration of the study was 40 days, the assessment of their condition was carried out on the 1st day (visit 1), after 15 days (visit 2) and after 40 days (visit 3) using the indicators of the above scales and tests in comparison with the background data. Safety assessment was carried out by the presence and structure of undesirable phenomena.

Results: The use of Brainmax led to a significant improvement in cognitive performance according to all generally accepted scales and tests (concentration and maintaining of attention, working memory, visual-constructive skills, volume and speed of attention speed, information processing and executive functions), as well as to the decrease severity of asthenia and improvement of the quality of life.

Conclusion: Brainmax has shown a good safety profile, tolerability and clinical efficacy in the treatment of young and middle-aged patients with non-demented cognitive impairment. Significant improvement was observed both with single and double course administration of the drug, but a significantly better effect was noted after its repeated course, which reflects, among other things, the cumulative effect of the active substances of this drug and makes longer use of the drug Brainmax justified and appropriate in these categories of patients. The data obtained allow us to recommend the wider use of the drug Brainmax in clinical practice for the treatment of CI in patients of different ages, which will optimize therapy and improve the course and outcome of the disease.

目的:评价Brainmax治疗非痴呆性认知障碍患者的临床疗效、安全性及其对功能恢复程度的影响。材料和方法:一项开放的多中心随机研究包括60例18-55岁的轻度和中度CI患者,有认知谱的抱怨。他们使用了一项临床和神经学研究,使用了普遍接受的量表和测试(MoCA、MMSE、MFI-20测试、Schulta、DSST测试和SF-36的生活质量评估)。患者按年龄和性别随机分为两组。第1组患者每日2次,连续治疗14 d。在休息10天后,他们又接受了14天相同的药物治疗。第2组患者给予Brainmax,每天2次,连用14天。研究总持续时间为40天,分别在第1天(访问1)、第15天(访问2)和第40天(访问3)使用上述量表的指标和测试与背景数据进行对比,对他们的状况进行评估。对不良现象的存在和结构进行了安全性评价。结果:根据所有普遍接受的量表和测试(注意力集中和保持、工作记忆、视觉构建技能、注意力速度和速度、信息处理和执行功能),使用Brainmax可显著改善认知表现,并降低衰弱的严重程度和改善生活质量。结论:Brainmax治疗中青年非痴呆性认知障碍患者具有良好的安全性、耐受性和临床疗效。单疗程和双疗程均有显著改善,但重复疗程后效果明显更好,这反映了该药活性物质的累积效应,并使长时间使用Brainmax药物在这些类别的患者中是合理和适当的。所获得的数据使我们推荐在临床实践中更广泛地使用Brainmax药物治疗不同年龄的CI患者,这将优化治疗方法,改善疾病的病程和结局。
{"title":"[Assessment of the safety and clinical efficacy of the Brainmax in therapy of non-demented patients with a mild cognitive impairment].","authors":"E V Ekusheva,&nbsp;V B Voitenkov","doi":"10.17116/jnevro202312302183","DOIUrl":"https://doi.org/10.17116/jnevro202312302183","url":null,"abstract":"<p><strong>Objective: </strong>The assessment of the clinical efficiency and safety of the drug Brainmax and its influence on the degree of functional recovery in the treatment of patients with non-dementia cognitive disorders with this drug.</p><p><strong>Material and methods: </strong>An open multicenter randomized study included 60 patients of 18-55 years with light and moderate CI, having complaints of the cognitive spectrum. They used a clinical and neurological study using generally accepted scales and tests (MoCA, MMSE, MFI-20 tests, Schulta, DSST tests and an assessment of the quality of life of SF-36). Patients were randomized in two groups comparable by age and gender. Group 1 was treated with Brainmax <i>per os</i> twice every day for 14 days. After 10-days rest they received same medication for another 14 days. Group 2 was treated with Brainmax <i>per os</i> twice every day for 14 days, without the continuation. The total duration of the study was 40 days, the assessment of their condition was carried out on the 1st day (visit 1), after 15 days (visit 2) and after 40 days (visit 3) using the indicators of the above scales and tests in comparison with the background data. Safety assessment was carried out by the presence and structure of undesirable phenomena.</p><p><strong>Results: </strong>The use of Brainmax led to a significant improvement in cognitive performance according to all generally accepted scales and tests (concentration and maintaining of attention, working memory, visual-constructive skills, volume and speed of attention speed, information processing and executive functions), as well as to the decrease severity of asthenia and improvement of the quality of life.</p><p><strong>Conclusion: </strong>Brainmax has shown a good safety profile, tolerability and clinical efficacy in the treatment of young and middle-aged patients with non-demented cognitive impairment. Significant improvement was observed both with single and double course administration of the drug, but a significantly better effect was noted after its repeated course, which reflects, among other things, the cumulative effect of the active substances of this drug and makes longer use of the drug Brainmax justified and appropriate in these categories of patients. The data obtained allow us to recommend the wider use of the drug Brainmax in clinical practice for the treatment of CI in patients of different ages, which will optimize therapy and improve the course and outcome of the disease.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical and psychological manifestations of emotional burnout in mothers of children with neuropsychiatric diseases (on a model of ADHD)]. [神经精神疾病患儿母亲情绪倦怠的临床和心理表现(基于ADHD模型)]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312302197
L S Chutko, S Yu Surushkina, E A Yakovenko, T I Anisimova, A V Sergeev, Y A Timosheva, S A Chekalova, E N Madjidova, M D Didur, D V Cherednichenko

Objective: To evaluate the therapeutic efficacy of Pantogam aktiv in the treatment of clinical manifestations of burnout in mothers of children with ADHD.

Material and methods: Under observation were 108 mothers of children with attention deficit hyperactivity disorder (ADHD) aged 25 to 50 years, who had symptoms of burnout in the clinical picture during the initial visit. The following research methods were used in the work: clinical history taking, neurological examination, S. Maslach questionnaire for assessing the burnout manifestations, subjective asthenia rating scale (MFI-20) with five subscales, digital fatigue rating scale (10-point variant), quantitative assessment of autonomic changes (questionnaire A.M. Wein), Spielberger-Khanin Scale for assessing emotional disorders, psychophysiological study of cognitive functions: test of attention variables TOVA (the Test of Variables of Attention). For the treatment of patients, the drug Pantogam Active was used in capsules of 300 mg, at a daily dose of 900 mg (2 capsules in the morning and 1 capsule in the afternoon) for 8 weeks.

Results: A re-examination after a course of treatment showed improvement in 68.5% of patients. After treatment, there was a significant decrease in the severity of such indicators of burnout as emotional exhaustion and depersonalization, a significant decrease in the average values according to the A.M. Wayne, a decrease in reactive anxiety, a statistically significant improvement in attention and a decrease in impulsivity (p<0.05).

Conclusion: Thus, the results of the study indicate that the use of Pantogam active in the treatment of clinical manifestations of parental burnout is characterized by high efficiency. After treatment, there is a significant decrease in fatigue, asthenia, anxiety, and total indicators characterizing burnout. The data obtained make it possible to recommend the use of Pantogam aktiv in the treatment of clinical manifestations of parents burnout in children with neurological diseases.

目的:评价泮妥甘对ADHD患儿母亲倦怠临床表现的治疗效果。材料与方法:研究对象为108名年龄在25 ~ 50岁的注意缺陷多动障碍(ADHD)患儿的母亲,初诊时临床表现为倦怠症状。本研究采用了以下研究方法:临床病史采集、神经学检查、评估倦怠表现的S. Maslach问卷、主观衰弱评定量表(MFI-20)(5个分量表)、数字疲劳评定量表(10分变型)、自主神经变化定量评估量表(A.M.Wein),斯皮尔伯格-哈宁量表(用于评估情绪障碍),认知功能的心理生理学研究:注意变量TOVA测试(注意变量测试)。对于患者的治疗,使用药物Pantogam Active 300 mg胶囊,每日剂量900 mg(上午2粒,下午1粒),持续8周。结果:68.5%的患者治疗后复查病情好转。治疗后,情绪耗竭和人格解体等倦怠指标的严重程度显著降低,A.M.的平均值显著降低结论:本研究结果表明,使用Pantogam活性药物治疗父母职业倦怠的临床表现具有高效率的特点。治疗后,疲劳、乏力、焦虑和倦怠的总体指标显著减少。所获得的数据使推荐使用Pantogam aktiv治疗神经系统疾病患儿父母倦怠的临床表现成为可能。
{"title":"[Clinical and psychological manifestations of emotional burnout in mothers of children with neuropsychiatric diseases (on a model of ADHD)].","authors":"L S Chutko,&nbsp;S Yu Surushkina,&nbsp;E A Yakovenko,&nbsp;T I Anisimova,&nbsp;A V Sergeev,&nbsp;Y A Timosheva,&nbsp;S A Chekalova,&nbsp;E N Madjidova,&nbsp;M D Didur,&nbsp;D V Cherednichenko","doi":"10.17116/jnevro202312302197","DOIUrl":"https://doi.org/10.17116/jnevro202312302197","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the therapeutic efficacy of Pantogam aktiv in the treatment of clinical manifestations of burnout in mothers of children with ADHD.</p><p><strong>Material and methods: </strong>Under observation were 108 mothers of children with attention deficit hyperactivity disorder (ADHD) aged 25 to 50 years, who had symptoms of burnout in the clinical picture during the initial visit. The following research methods were used in the work: clinical history taking, neurological examination, S. Maslach questionnaire for assessing the burnout manifestations, subjective asthenia rating scale (MFI-20) with five subscales, digital fatigue rating scale (10-point variant), quantitative assessment of autonomic changes (questionnaire A.M. Wein), Spielberger-Khanin Scale for assessing emotional disorders, psychophysiological study of cognitive functions: test of attention variables TOVA (the Test of Variables of Attention). For the treatment of patients, the drug Pantogam Active was used in capsules of 300 mg, at a daily dose of 900 mg (2 capsules in the morning and 1 capsule in the afternoon) for 8 weeks.</p><p><strong>Results: </strong>A re-examination after a course of treatment showed improvement in 68.5% of patients. After treatment, there was a significant decrease in the severity of such indicators of burnout as emotional exhaustion and depersonalization, a significant decrease in the average values according to the A.M. Wayne, a decrease in reactive anxiety, a statistically significant improvement in attention and a decrease in impulsivity (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>Thus, the results of the study indicate that the use of Pantogam active in the treatment of clinical manifestations of parental burnout is characterized by high efficiency. After treatment, there is a significant decrease in fatigue, asthenia, anxiety, and total indicators characterizing burnout. The data obtained make it possible to recommend the use of Pantogam aktiv in the treatment of clinical manifestations of parents burnout in children with neurological diseases.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10798351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Risk factors and adherence to treatment of patients with cerebrovascular diseases]. [脑血管疾病患者的危险因素与治疗依从性]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312308284
L I Pyshkina, A A Tyazhelnikov, A A Kabanov, D T Sherazadishvili, Z H Osmaeva, S V Prikazchikov, P R Kamchatnov

Objective: To assess the representation of risk factors and treatment adherence in patients with cerebrovascular diseases.

Material and methods: A single-stage cross-sectional non-comparable study was conducted, which included 492 patients, of whom 133 had an ischemic stroke/transient ischemic attack (main group, MG), 344 had chronic cerebrovascular pathology (comparison group, CG). The representation of risk factors, the state of cognitive functions, the severity of anxiety and depression were evaluated.

Results: MG respondents visit specialized specialists more often than CG (p<0.001), are more committed to taking antiplatelet agents (p<0.003), statins (p<0.005), antihypertensive drugs (p<0.005). Regular intake of antithrombotic drugs was associated with the history of ischemic stroke (r=0.483; p<0.01), type 2 diabetes (r=0.637; p<0.011), atrial fibrillation (r=0.481; p<0.001), living in a family (r=0.493; p<0.03). An inverse correlation was established between the systematic intake of antiplatelet drugs and the age of the respondents (r=-0.637; p<0.002), cognitive impairment (r=-0.433; p<0.05), the history of the gastrointestinal tract diseases (gastric ulcer and duodenal ulcer) (r=-0.563; p<0.001). Irregular medication intake was observed in patients aged over 60 years compared with younger (17.3% and 6.4%, respectively, p=0.001), patients living in a family compared with single (85.6% and 65.1%, p=0.032). The history of ischemic stroke or myocardial infarction is associated with increased adherence to regular medication.

Conclusion: The study of risk factors and the assessment of treatment adherence can ensure the formation of an effective strategy for primary and secondary prevention of cerebrovascular diseases.

目的:评价脑血管病患者危险因素的表现及治疗依从性。材料与方法:采用单期横断面非可比性研究,纳入492例患者,其中缺血性卒中/短暂性脑缺血发作133例(主组,MG),慢性脑血管病变344例(对照组,CG)。评估危险因素的代表性、认知功能状态、焦虑和抑郁的严重程度。结果:MG受访者就诊专科次数多于CG受访者(ppppr=0.483;公关= 0.637;公关= 0.481;公关= 0.493;公关= -0.637;公关= -0.433;公关= -0.563;p=0.001),有家庭的患者与单身患者相比(85.6%和65.1%,p=0.032)。缺血性中风或心肌梗死的病史与增加对常规药物的依从性有关。结论:脑血管病危险因素的研究和治疗依从性的评价可以确保形成有效的脑血管病一级和二级预防策略。
{"title":"[Risk factors and adherence to treatment of patients with cerebrovascular diseases].","authors":"L I Pyshkina,&nbsp;A A Tyazhelnikov,&nbsp;A A Kabanov,&nbsp;D T Sherazadishvili,&nbsp;Z H Osmaeva,&nbsp;S V Prikazchikov,&nbsp;P R Kamchatnov","doi":"10.17116/jnevro202312308284","DOIUrl":"https://doi.org/10.17116/jnevro202312308284","url":null,"abstract":"<p><strong>Objective: </strong>To assess the representation of risk factors and treatment adherence in patients with cerebrovascular diseases.</p><p><strong>Material and methods: </strong>A single-stage cross-sectional non-comparable study was conducted, which included 492 patients, of whom 133 had an ischemic stroke/transient ischemic attack (main group, MG), 344 had chronic cerebrovascular pathology (comparison group, CG). The representation of risk factors, the state of cognitive functions, the severity of anxiety and depression were evaluated.</p><p><strong>Results: </strong>MG respondents visit specialized specialists more often than CG (<i>p</i><0.001), are more committed to taking antiplatelet agents (<i>p</i><0.003), statins (<i>p</i><0.005), antihypertensive drugs (<i>p</i><0.005). Regular intake of antithrombotic drugs was associated with the history of ischemic stroke (<i>r</i>=0.483; <i>p</i><0.01), type 2 diabetes (<i>r</i>=0.637; <i>p</i><0.011), atrial fibrillation (<i>r</i>=0.481; <i>p</i><0.001), living in a family (<i>r</i>=0.493; <i>p</i><0.03). An inverse correlation was established between the systematic intake of antiplatelet drugs and the age of the respondents (<i>r</i>=-0.637; <i>p</i><0.002), cognitive impairment (<i>r</i>=-0.433; <i>p</i><0.05), the history of the gastrointestinal tract diseases (gastric ulcer and duodenal ulcer) (<i>r</i>=-0.563; <i>p</i><0.001). Irregular medication intake was observed in patients aged over 60 years compared with younger (17.3% and 6.4%, respectively, <i>p</i>=0.001), patients living in a family compared with single (85.6% and 65.1%, <i>p</i>=0.032). The history of ischemic stroke or myocardial infarction is associated with increased adherence to regular medication.</p><p><strong>Conclusion: </strong>The study of risk factors and the assessment of treatment adherence can ensure the formation of an effective strategy for primary and secondary prevention of cerebrovascular diseases.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10200394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Reduced numerical density of oligodendrocytes and oligodendrocyte clusters in the head of the caudate nucleus in schizophrenia]. [精神分裂症患者尾状核头部少突胶质细胞和少突胶质细胞簇的数值密度降低]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123011103
N S Kolomeets, N A Uranova

Objective: Morphometric estimation of the numerical density of oligodendrocytes (NcOl) and numerical density of oligodendrocyte clusters (NvOlC) in the rostral part of the caudate head nucleus associated with the cortical regions of the default network in the norm and in schizophrenia.

Material and methods: NcOl and NvOlC were determined in the gray matter of the rostral part of the head of the caudate nucleus in Nissl-stained sections using optical dissector in postmortem brains in 18 schizophrenia and 18 healthy control cases.

Results: The NvOl (-20%, p<0.001) and NvOlC (-28%, p<0.001) were decreased in the schizophrenia group as compared to the control groups. The NvOl correlated with the NvOlC (R≥0.88, p<0.001) in both groups while a lack of correlations was previously found in the central part of the caudate head.

Conclusion: The detected deficits of the NcOl and NvOlC is an agreement with prominent suppressing of cortico-striatal connections and reduced density of gray matter in this part of the caudate in schizophrenia. The differences in the pattern of correlations as compared to the central part of this structure might be associated with the specific features of functional activity of default-mode and fronto-parietal networks associated with these parts of caudate nucleus.

目的:形态计量学估计正常人和精神分裂症患者尾状头核吻侧与默认网络皮质区相关的少突胶质细胞(NcOl)和少突胶质细胞簇(NvOlC)的数值密度。材料与方法:对18例精神分裂症患者和18例健康对照者的死后脑进行nsl染色,测定尾状核头吻侧灰质中的NcOl和NvOlC含量。结果:与对照组相比,精神分裂症组NvOl (-20%, p0.001)和NvOlC (-28%, p0.001)下降。两组的NvOl与NvOlC相关(R≥0.88,p0.001),而之前在尾状头的中央部分没有发现相关性。结论:精神分裂症患者NcOl和NvOlC的缺陷与皮质纹状体连接的显著抑制和尾状体部分灰质密度的降低是一致的。与该结构的中心部分相比,相关模式的差异可能与与尾状核这些部分相关的默认模式和额顶叶网络的功能活动的特定特征有关。
{"title":"[Reduced numerical density of oligodendrocytes and oligodendrocyte clusters in the head of the caudate nucleus in schizophrenia].","authors":"N S Kolomeets,&nbsp;N A Uranova","doi":"10.17116/jnevro2023123011103","DOIUrl":"https://doi.org/10.17116/jnevro2023123011103","url":null,"abstract":"<p><strong>Objective: </strong>Morphometric estimation of the numerical density of oligodendrocytes (NcOl) and numerical density of oligodendrocyte clusters (NvOlC) in the rostral part of the caudate head nucleus associated with the cortical regions of the default network in the norm and in schizophrenia.</p><p><strong>Material and methods: </strong>NcOl and NvOlC were determined in the gray matter of the rostral part of the head of the caudate nucleus in Nissl-stained sections using optical dissector in postmortem brains in 18 schizophrenia and 18 healthy control cases.</p><p><strong>Results: </strong>The NvOl (-20%, <i>p<</i>0.001) and NvOlC (-28%, <i>p<</i>0.001) were decreased in the schizophrenia group as compared to the control groups. The NvOl correlated with the NvOlC (R≥0.88, <i>p<</i>0.001) in both groups while a lack of correlations was previously found in the central part of the caudate head.</p><p><strong>Conclusion: </strong>The detected deficits of the NcOl and NvOlC is an agreement with prominent suppressing of cortico-striatal connections and reduced density of gray matter in this part of the caudate in schizophrenia. The differences in the pattern of correlations as compared to the central part of this structure might be associated with the specific features of functional activity of default-mode and fronto-parietal networks associated with these parts of caudate nucleus.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10583684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1